Shares of Humacyte, Inc. (HUMA) soared over 10% in pre-market trading on Thursday, following positive analyst ratings from two Wall Street firms.
TD Cowen analyst Josh Jennings reiterated a "Buy" rating on HUMA and set a price target of $10.00. Meanwhile, Piper Sandler analyst Allison Bratzel maintained a "Hold" rating but raised the firm's price target to $6.00.
The analyst ratings suggest a positive sentiment towards Humacyte's prospects, driving investor optimism and contributing to the pre-market surge in the company's stock price.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。